Roth Capital raised the firm’s price target on Ceva (CEVA) to $35 from $30 and keeps a Buy rating on the shares. The company’s Q3 results topped estimates, and the firm is encouraged by broad end market royalty growth and robust licensing results, the analyst tells investors in a research note. The growing NeuPro AI IP licensing contribution bodes well for the secular growth opportunity, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CEVA: